Protagonist Therapeutics Inc Earnings Dividend

Protagonist Therapeutics Inc’s revenue jumped 99.03% since last year same period to $56.37Mn in the Q1 2026. On a quarterly growth basis, Protagonist Therapeutics Inc has generated 657.94% jump in its revenue since last 3-months.

Protagonist Therapeutics Inc’s net profit jumped 132.46% since last year same period to $3.78Mn in the Q1 2026. On a quarterly growth basis, Protagonist Therapeutics Inc has generated 108.52% jump in its net profits since last 3-months.

Protagonist Therapeutics Inc’s net profit margin jumped 116.31% since last year same period to 6.71% in the Q1 2026. On a quarterly growth basis, Protagonist Therapeutics Inc has generated 101.12% jump in its net profit margins since last 3-months.

Protagonist Therapeutics Inc’s earning per share (EPS) estimates for the current quarter stand at -0.5 - a -48.08% fall from last quarter’s estimates.

Protagonist Therapeutics Inc’s earning per share (EPS) estimates for the current year stand at -0.5.

Protagonist Therapeutics Inc’s earning per share (EPS) jumped 126.32% since last year same period to 0.05 in the Q1 2026. This indicates that the Protagonist Therapeutics Inc has generated 126.32% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Protagonist Therapeutics Inc’s return on assets (ROA) stands at -0.12.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Protagonist Therapeutics Inc’s return on equity (ROE) stands at -0.17.